This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Roberto A. Cohen, MD
Buenos Aires, Argentina

Marguerite B. McDonald, MD
New Orleans, La

Arch Ophthalmol. 1993;111(9):1167-1168.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Conjunctival autografts are successfully used for the surgical treatment of pterygium. Recurrence is the most common complication after pterygium removal and repeated surgery may lead in some cases to serious complications, including restriction of eye movements, scleral thinning, corneal thinning, and corneal perforation.¹

The usual technique involves excision of the pterygium and replacement with superotemporal bulbar conjunctiva. The exposed sclera and medial rectus muscle are covered and the graft is secured with multiple interrupted sutures. Care is required to position the conjunctival graft over the sclera.

Tisseel (Immuno AG, Vienna, Austria) is a biological adhesive in which human fibrinogen and thrombin are combined to form a fibrin glue. The applicator permits the mixing of precise amounts of the two components at the time of use. The concentration of thrombin determines the speed of hardening, ranging from a few seconds to as much as 30 seconds. Full-tensile strength is reached . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?